Amgen Sees Shift in Shareholder Composition Amid Institutional Investment
Amgen Inc., a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California, has seen significant changes to its shareholder composition. MASTERINVEST Kapitalanlage GmbH acquired a new stake in Amgen's shares in the second quarter, purchasing 11,907 shares valued at approximately $4,312,000.
This is not an isolated instance of institutional investment; other notable investors have also increased their stakes in the company. BlackRock Inc. raised its holdings by 4.8% during the second quarter, now owning 49,362,016 shares worth $17,874,974,000. State Street Corp boosted its position by 4.4% in the fourth quarter, owning 30,591,403 shares valued at $10,012,872,000.
Despite these changes, Amgen's stock has been somewhat volatile, with a current price of $436.99 and a 12-month high of $447.03. The company's 50-day moving average is $386.75, and its 200-day moving average is $364.23.